COMP <GO>
TEVA vs LLY // OPERATING MARGIN
Teva Pharmaceutical Industries Limited (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: TEVA 2
— LLY 13
▲ OPERATING MARGIN LEADER: LLY
LAST: $42.09 (+1.50%) • MKT CAP: $48.32B
operating-margins
12.50%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
operating-margins
40.21%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TEVA VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TEVA | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 51.80% | 83.64% | -31.84 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.40% | 32.36% | -22.96 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.8x | 36.4x | -15.62 | TEVA | /valuation <GO> |
| Free Cash Flow Yield | 1.81% | 2.30% | -0.49 | LLY | /fcf-yield <GO> |
| Operating Margin ACTIVE | 12.50% | 40.21% | -27.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | 8.20% | 31.90% | -23.70 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | 45.51% | -41.21 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.02 | 9.29 | -8.27 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.77% | +0.13 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.7 | 77.9 | -14.20 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.51 | +0.49 | TEVA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.9x | 26.3x | +5.65 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $48.32B | $1.33T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TEVA REV | LLY REV | TEVA GROSS % | LLY GROSS % | TEVA FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $17.26B | $65.18B | 51.8% | 83.0% | $872.4M | $16.81B |
| FY 2024 | $16.54B | $45.04B | 48.7% | 81.3% | $502.5M | $8.82B |
| FY 2023 | $15.85B | $34.12B | 44.0% | 79.3% | $654.9M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TEVA // BETA 1.00
LLY // BETA 0.51